Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2023

Open Access 01-12-2023 | Metastasis | Review

Metformin and long non-coding RNAs in breast cancer

Authors: Morteza Gholami, Zeynab Nickhah Klashami, Pirooz Ebrahimi, Amir Ali Mahboobipour, Amir Salehi Farid, Aida Vahidi, Marziyeh Zoughi, Mojgan Asadi, Mahsa M. Amoli

Published in: Journal of Translational Medicine | Issue 1/2023

Login to get access

Abstract

Breast cancer (BC) is the second most common cancer and cause of death in women. In recent years many studies investigated the association of long non-coding RNAs (lncRNAs), as novel genetic factors, on BC risk, survival, clinical and pathological features. Recent studies also investigated the roles of metformin treatment as the firstline treatment for type 2 diabetes (T2D) played in lncRNAs expression/regulation or BC incidence, outcome, mortality and survival, separately. This comprehensive study aimed to review lncRNAs associated with BC features and identify metformin-regulated lncRNAs and their mechanisms of action on BC or other types of cancers. Finally, metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, by several molecular mechanisms have been described in this review. In addition, metformin action on other types of cancers by regulating ten lncRNAs including AC006160.1, Loc100506691, lncRNA-AF085935, SNHG7, HULC, UCA1, H19, MALAT1, AFAP1-AS1, AC026904.1 is described.
Appendix
Available only for authorised users
Literature
1.
2.
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.PubMedPubMedCentralCrossRef
3.
Han B, Cui H, Kang L, Zhang X, Jin Z, Lu L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. Tumor Biol. 2015;36(8):6295–304.CrossRef
4.
Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z. Metformin reverses multidrug resistance and epithelial–mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem. 2014;386(1):63–71.PubMedCrossRef
5.
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369–80.PubMedCrossRef
6.
Liu B, Fan Z, Edgerton SM, Deng X-S, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.PubMedCrossRef
7.
Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY, et al. Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON. 2013;18(1):51–6.PubMed
8.
9.
Mondal P, Meeran SM. Long non-coding RNAs in breast cancer metastasis. Non-coding RNA Res. 2020;5(4):208–18.CrossRef
10.
Zeind CS, Carvalho MG. Koda-Kimble and Young’s applied therapeutics: the clinical use of drugs. 11th ed. Philadelphia: LWW; 2018.
11.
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.PubMedPubMedCentralCrossRef
12.
13.
De Francesco EM, Cirillo F, Vella V, Belfiore A, Maggiolini M, Lappano R. Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opin Ther Targets. 2022;26(6):513–35.PubMedCrossRef
14.
Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10(6):1014–24.PubMedCrossRef
15.
16.
Huang Q-Y, Liu G-F, Qian X-L, Tang L-B, Huang Q-Y, Xiong L-X. Long non-coding RNA: dual effects on breast cancer metastasis and clinical applications. Cancers. 2019;11(11):1802.PubMedPubMedCentralCrossRef
17.
Zibara K, Awada Z, Dib L, El-Saghir J, Al-Ghadban S, Ibrik A, et al. Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo. Sci Rep. 2015;5(1):1–16.CrossRef
18.
Lappano R, Rigiracciolo DC, Belfiore A, Maggiolini M, De Francesco EM. Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opin Ther Targets. 2020;24(6):559–72.PubMedCrossRef
19.
20.
Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 2003;5(3):1–7.CrossRef
21.
22.
23.
Afzal S, Hassan M, Ullah S, Abbas H, Tawakkal F, Khan MA. Breast cancer; discovery of novel diagnostic biomarkers, drug resistance, and therapeutic implications. Front Mol Biosci. 2022;9: 783450.PubMedPubMedCentralCrossRef
24.
Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci. 2001;945(1):172–8.PubMedCrossRef
25.
Yin W-B, Yan M-G, Fang X, Guo J-J, Xiong W, Zhang R-P. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018;487:363–8.PubMedCrossRef
26.
27.
Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, et al. A systematic evaluation of miRNA: mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med. 2013;11(1):1–14.CrossRef
28.
Masuda M, Miki Y, Hata S, Takagi K, Sakurai M, Ono K, et al. An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med. 2012;10(1):1–9.
29.
Chang C-H, Fan T-C, Yu J-C, Liao G-S, Lin Y-C, Shih AC-C, et al. The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. J Transl Med. 2014;12(1):1–12.CrossRef
30.
Vivacqua A, Muoio MG, Miglietta AM, Maggiolini M. Differential MicroRNA landscape triggered by estrogens in cancer associated fibroblasts (CAFs) of primary and metastatic breast tumors. Cancers. 2019;11(3):412.PubMedPubMedCentralCrossRef
31.
32.
Fu A, Jacobs DI, Hoffman AE, Zheng T, Zhu Y. PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome. Carcinogenesis. 2015;36(10):1094–102.PubMedPubMedCentralCrossRef
33.
Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):1–15.CrossRef
34.
Faria J, Negalha G, Azevedo A, Martel F. Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24(2):111–23.PubMedCrossRef
35.
36.
Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9(1):1–6.CrossRef
37.
38.
Drzewoski J, Hanefeld M. The current and potential therapeutic use of metformin—the good old drug. Pharmaceuticals (Basel). 2021;14(2):122.PubMedCrossRef
39.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S73–85.CrossRef
40.
Leonaviciute D, Madsen B, Schmedes A, Buus NH, Rasmussen BS. Severe metformin poisoning successfully treated with simultaneous venovenous hemofiltration and prolonged intermittent hemodialysis. Case Rep Crit Care. 2018;2018:3868051.PubMedPubMedCentral
41.
Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomark Prev. 2009;18(3):701–5.CrossRef
42.
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist. 2015;20(11):1236–44.PubMedPubMedCentralCrossRef
43.
Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12(3):169–82.PubMedCrossRef
44.
Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L, Menendez JA. Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKαThr172) in human cancer cells. Cell Cycle. 2009;8(5):788–91.PubMedCrossRef
45.
Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. 2015;17(1):1–12.CrossRef
46.
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 2010;3(9):1066–76.PubMedCrossRef
47.
Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn. 2011;121(3):81–7.PubMed
48.
49.
LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med. 1995;122(1):54–9.PubMedCrossRef
50.
Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11(5):390–401.PubMedPubMedCentralCrossRef
51.
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88–96.PubMedCrossRef
52.
Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci. 2010;118(5):315–32.CrossRef
53.
54.
Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci. 2013;110(3):972–7.PubMedCrossRef
55.
Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer. 2014;14(1):1–11.CrossRef
56.
Arai M, Uchiba M, Komura H, Mizuochi Y, Harada N, Okajima K. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther. 2010;334(1):206–13.PubMedCrossRef
57.
Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 2012;3(1):1–11.CrossRef
58.
Wahdan-Alaswad RS, Thor AD. Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions. Metformin. London: IntechOpen; 2020.
59.
60.
Kaleağasıoğlu F, Ali DM, Berger MR. Multiple facets of autophagy and the emerging role of alkylphosphocholines as autophagy modulators. Front Pharmacol. 2020;11:547.PubMedPubMedCentralCrossRef
61.
Lu G, Wu Z, Shang J, Xie Z, Chen C, Zhang C. The effects of metformin on autophagy. Biomed Pharmacother. 2021;137: 111286.PubMedCrossRef
62.
Huang Y, Zhou Z, Zhang J, Hao Z, He Y, Wu Z, et al. lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell. J Cell Mol Med. 2021;25(15):7135–45.PubMedPubMedCentralCrossRef
63.
64.
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193–201.PubMedCrossRef
65.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92(18):1472–89.PubMedCrossRef
66.
67.
68.
69.
Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, et al. Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. J Transl Med. 2022;20(1):1–19.CrossRef
70.
71.
Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012;135(3):639–46.PubMedCrossRef
72.
Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE. 2013;8(8): e71583.PubMedPubMedCentralCrossRef
73.
Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Schünemann HJ, et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysismetformin therapy and breast cancer incidence and mortality. Cancer Epidemiol Biomark Prev. 2018;27(6):627–35.CrossRef
74.
Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37(3):207–18.PubMedCrossRef
75.
Yang T, Yang Y, Liu S. Association between metformin therapy and breast cancer incidence and mortality: evidence from a meta-analysis. J Breast Cancer. 2015;18(3):264–70.PubMedPubMedCentralCrossRef
76.
Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(8):707–10.PubMedCrossRef
77.
Coyle C, Cafferty F, Vale C, Langley R. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–95.PubMedPubMedCentralCrossRef
78.
Cao X, Wu Y, Wang J, Liu K, Wang X. The effect of metformin on mortality among diabetic cancer patients: a systematic review and meta-analysis. JNCI Cancer Spectrum. 2017;1(1): pkx007.PubMedPubMedCentralCrossRef
79.
Wu Z, Qu B, Huang X, Song Y, Gao P, Shi J, et al. The potential adjunctive benefit of adding metformin to standard treatment in inoperable cancer patients: a meta-analysis of randomized controlled trials. Ann Transl Med. 2020;8(21):1404.PubMedPubMedCentralCrossRef
80.
Morio K, Kurata Y, Kawaguchi-Sakita N, Shiroshita A, Kataoka Y. Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy: systematic review and meta-analysis. Ann Pharmacother. 2022;56(3):245–55.PubMedCrossRef
81.
Wang Q, Ma X, Long J, Du X, Pan B, Mao H. Metformin and survival of women with breast cancer: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(3):263–9.PubMedCrossRef
82.
Zhang Z-J, Yuan J, Bi Y, Wang C, Liu Y. The effect of metformin on biomarkers and survivals for breast cancer-a systematic review and meta-analysis of randomized clinical trials. Pharmacol Res. 2019;141:551–5.PubMedCrossRef
83.
Farkhondeh T, Amirabadizadeh A, Aramjoo H, Llorens S, Roshanravan B, Saeedi F, et al. Impact of metformin on cancer biomarkers in non-diabetic cancer patients: a systematic review and meta-analysis of clinical trials. Curr Oncol. 2021;28(2):1412–23.PubMedPubMedCentralCrossRef
84.
Rahmani J, Manzari N, Thompson J, Gudi S, Chhabra M, Naik G, et al. The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials. Clin Transl Oncol. 2020;22(1):37–49.PubMedCrossRef
85.
Barakat HE, Hussein RR, Elberry AA, Zaki MA, Elsherbiny RM. Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2022;22(4):415–36.PubMedCrossRef
86.
Park Y-M, Bookwalter D, O’Brien K, Jackson C, Weinberg C, Sandler D. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol. 2021;32(3):351–9.PubMedCrossRef
87.
García-Esquinas E, Guinó E, Castano-Vinyals G, Pérez-Gómez B, Llorca J, Altzibar JM, et al. Association of diabetes and diabetes treatment with incidence of breast cancer. Acta Diabetol. 2016;53(1):99–107.PubMedCrossRef
88.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA. 32 randomized clinical trial. JAMA. 2022;327(20):1963–73.PubMedPubMedCentralCrossRef
89.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46.PubMedCrossRef
90.
Marciniak M, iEwolucjonizmu ZG. Imprinting genomowy u ssaków: Najnowsze doniesienia. Post Biol Kom. 2008;35:243–52.
91.
Johnsson P, Lipovich L, Grandér D, Morris KV. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta. 2014;1840(3):1063–71.PubMedCrossRef
92.
Kumar V, Westra H-J, Karjalainen J, Zhernakova DV, Esko T, Hrdlickova B, et al. Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genet. 2013;9(1): e1003201.PubMedPubMedCentralCrossRef
93.
Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.PubMedCrossRef
94.
Fathi DB. Strategies to target long non-coding RNAs in cancer treatment: progress and challenges. Egypt J Med Hum Genet. 2020;21(1):41.CrossRef
95.
Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Non-coding RNA Res. 2018;3(3):108–17.CrossRef
96.
Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, et al. Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers. Front Oncol. 2020;10: 598817.PubMedPubMedCentralCrossRef
97.
Sebastian-delaCruz M, Gonzalez-Moro I, Olazagoitia-Garmendia A, Castellanos-Rubio A, Santin I. The role of lncRNAs in gene expression regulation through mRNA stabilization. Noncoding RNA. 2021;7(1):3.PubMedPubMedCentralCrossRef
98.
Giannakakis A, Zhang J, Jenjaroenpun P, Nama S, Zainolabidin N, Aau MY, et al. Contrasting expression patterns of coding and noncoding parts of the human genome upon oxidative stress. Sci Rep. 2015;5:9737.PubMedPubMedCentralCrossRef
99.
Begolli R, Sideris N, Giakountis A. LncRNAs as chromatin regulators in cancer: from molecular function to clinical potential. Cancers (Basel). 2019;11(10):1524.PubMedCrossRef
100.
101.
Sang Y, Tang J, Li S, Li L, Tang X, Cheng C, et al. LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression. Sci Rep. 2016;6:22366.PubMedPubMedCentralCrossRef
102.
Cantile M, Di Bonito M, Cerrone M, Collina F, De Laurentiis M, Botti G. Long non-coding RNA HOTAIR in breast cancer therapy. Cancers (Basel). 2020;12(5):1197.PubMedPubMedCentralCrossRef
103.
Weidle UH, Birzele F, Kollmorgen G, Rueger R. Long non-coding RNAs and their role in metastasis. Cancer Genom Proteom. 2017;14(3):143–60.CrossRef
104.
Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.PubMedCrossRef
105.
Jiang M-C, Ni J-J, Cui W-Y, Wang B-Y, Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354.PubMedPubMedCentral
106.
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, et al. lncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Molr Ther Nucleic Acids. 2021;25:613–37.CrossRef
107.
Sherif S, Mall R, Almeer H, Naik A, Al Homaid A, Thomas R, et al. Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting. J Transl Med. 2022;20(1):1–20.CrossRef
108.
Lai J, Chen B, Zhang G, Li X, Mok H, Liao N. Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature. J Transl Med. 2020;18(1):1–10.CrossRef
109.
Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, et al. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med. 2020;18(1):1–13.CrossRef
110.
Mehrpour Layeghi S, Arabpour M, Shakoori A, Naghizadeh MM, Mansoori Y, Tavakkoly Bazzaz J, et al. Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer. J Transl Med. 2021;19(1):1–17.CrossRef
111.
Li G-Y, Wang W, Sun J-Y, Xin B, Zhang X, Wang T, et al. Long non-coding RNAs AC026904. 1 and UCA1: a “one-two punch” for TGF-β-induced SNAI2 activation and epithelial–mesenchymal transition in breast cancer. Theranostics. 2018;8(10):2846.PubMedPubMedCentralCrossRef
112.
Wu J, Xu W, Ma L, Sheng J, Ye M, Chen H, et al. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. Aging (Albany NY). 2021;13(14):18191.PubMedCrossRef
113.
Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 2017;24(1):59–71.PubMedCrossRef
114.
115.
Yang F, Shen Y, Zhang W, Jin J, Huang D, Fang H, et al. An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. Cell Death Differ. 2018;25(12):2209–20.PubMedPubMedCentralCrossRef
116.
Li R-H, Chen M, Liu J, Shao C-C, Guo C-P, Wei X-L, et al. Long noncoding RNA ATB promotes the epithelial−mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer. Cell Death Dis. 2018;9(12):1–16.CrossRef
117.
Barton M, Santucci-Pereira J, Vaccaro OG, Nguyen T, Su Y, Russo J. BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis. BMC Cancer. 2019;19(1):1–17.CrossRef
118.
Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, et al. lncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell. 2014;159(5):1110–25.PubMedPubMedCentralCrossRef
119.
Lin X, Dinglin X, Cao S, Zheng S, Wu C, Chen W, et al. Enhancer-driven lncRNA BDNF-AS induces endocrine resistance and malignant progression of breast cancer through the RNH1/TRIM21/mTOR cascade. Cell Rep. 2020;31(10): 107753.PubMedCrossRef
120.
Hu X, Liu Y, Du Y, Cheng T, Xia W. Long non-coding RNA BLACAT1 promotes breast cancer cell proliferation and metastasis by miR-150-5p/CCR2. Cell Biosci. 2019;9(1):1–9.CrossRef
121.
Gooding AJ, Zhang B, Jahanbani FK, Gilmore HL, Chang JC, Valadkhan S, et al. The lncRNA BORG drives breast cancer metastasis and disease recurrence. Sci Rep. 2017;7(1):1–18.CrossRef
122.
Zhang Y, Zhu M, Sun Y, Li W, Wang Y, Yu W. Upregulation of lncRNA CASC2 suppresses cell proliferation and metastasis of breast cancer via inactivation of the TGF-β signaling pathway. Oncol Res. 2019;27(3):379.PubMedPubMedCentralCrossRef
123.
Han C, Li X, Fan Q, Liu G, Yin J. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling. Aging (Albany NY). 2019;11(14):4858.PubMedCrossRef
124.
Wu Z, Li Y, Wu Y, Wang Y, Nian W, Wang L, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(4):706–14.PubMed
125.
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33(4):706-720.e9.PubMedPubMedCentralCrossRef
126.
Keshavarz M, Asadi MH. Long non-coding RNA ES 1 controls the proliferation of breast cancer cells by regulating the Oct4/Sox2/miR-302 axis. FEBS J. 2019;286(13):2611–23.PubMedCrossRef
127.
Bai Y, Zhou X, Huang L, Wan Y, Li X, Wang Y. Long noncoding RNA EZR-AS1 promotes tumor growth and metastasis by modulating Wnt/β-catenin pathway in breast cancer. Exp Ther Med. 2018;16(3):2235–42.PubMedPubMedCentral
128.
Zhang Z, Sun L, Zhang Y, Lu G, Li Y, Wei Z. Long non-coding RNA FEZF1-AS1 promotes breast cancer stemness and tumorigenesis via targeting miR-30a/Nanog axis. J Cell Physiol. 2018;233(11):8630–8.PubMedCrossRef
129.
Ma F, Liu X, Zhou S, Li W, Liu C, Chadwick M, et al. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. Cancer Lett. 2019;450:63–75.PubMedCrossRef
130.
Hu H, Wang Y, Zhang T, Zhang C, Liu Y, Li G, et al. Association of LncRNA-GACAT3 with MRI features of breast cancer and its molecular mechanism. J BUON. 2019;24:2377–84.PubMed
131.
Esmatabadi MJD, Motamedrad M, Sadeghizadeh M. Down-regulation of lncRNA, GAS5 decreases chemotherapeutic effect of dendrosomal curcumin (DNC) in breast cancer cells. Phytomedicine. 2018;42:56–65.PubMedCrossRef
132.
Song R, Zhang J, Huang J, Hai T. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition. Cancer Biomark. 2018;22(3):565–73.PubMedCrossRef
133.
Si H, Chen P, Li H, Wang X. Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer. Am J Transl Res. 2019;11(5):3213.PubMedPubMedCentral
134.
Wang Y, Zhang G, Han J. HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer. J Cell Biochem. 2019;120(6):10513–8.PubMedCrossRef
135.
Lu PW, Li L, Wang F, Gu YT. Retracted: Effects of long non‐coding RNA HOST2 on cell migration and invasion by regulating MicroRNA let‐7b in breast cancer. Wiley Online Library; 2018.
136.
Mozdarani H, Ezzatizadeh V, Rahbar PR. The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. J Transl Med. 2020;18(1):1–15.CrossRef
137.
Liu M, Gou L, Xia J, Wan Q, Jiang Y, Sun S, et al. LncRNA ITGB2-AS1 could promote the migration and invasion of breast cancer cells through up-regulating ITGB2. Int J Mol Sci. 2018;19(7):1866.PubMedPubMedCentralCrossRef
138.
Zhou C, Wang X, Yang N, Xue S, Li W, Xie P. LncRNA LET function as a tumor suppressor in breast cancer development. Eur Rev Med Pharmacol Sci. 2018;22(18):6002–7.PubMed
139.
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016;8(9):1052–64.PubMedPubMedCentralCrossRef
140.
141.
Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, et al. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother. 2018;97:1275–81.PubMedCrossRef
142.
Dong L, Qian J, Chen F, Fan Y, Long J. LINC00461 promotes cell migration and invasion in breast cancer through miR-30a-5p/integrin β3 axis. J Cell Biochem. 2019;120(4):4851–62.PubMedCrossRef
143.
Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 2018;37(1):1–11.CrossRef
144.
Chen D, Zheng X, Cao Y, He X, Nian W, Zeng X, et al. Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 2017;21(2):275–83.PubMed
145.
Xia E, Shen Y, Bhandari A, Zhou X, Wang Y, Yang F, et al. Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7–H6 and epithelial–mesenchymal transition. Am J Cancer Res. 2018;8(7):1273.PubMedPubMedCentral
146.
Zhou W, Gong J, Chen Y, Chen J, Zhuang Q, Cao J, et al. Long noncoding RNA LINC00899 suppresses breast cancer progression by inhibiting miR-425. Aging (Albany NY). 2019;11(22):10144.PubMedCrossRef
147.
Song Z, Zhang X, Lin Y, Wei Y, Liang S, Dong C. LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2. J Cell Mol Med. 2019;23(11):7554–65.PubMedPubMedCentralCrossRef
148.
Jiang M, Xiao Y, Liu D, Luo N, Gao Q, Guan Y. Overexpression of long noncoding RNA LINC01296 indicates an unfavorable prognosis and promotes tumorigenesis in breast cancer. Gene. 2018;675:217–24.PubMedCrossRef
149.
Li Y, Song Y, Wang Z, Zhang Z, Lu M, Wang Y. Long non-coding RNA LINC01787 drives breast cancer progression via disrupting miR-125b generation. Front Oncol. 2019;9:1140.PubMedPubMedCentralCrossRef
150.
Xiong Y, Gu Y, Wang F, Li L, Zhu M, Wang N, et al. LINC01857 as an oncogene regulates CREB1 activation by interacting with CREBBP in breast cancer. J Cell Physiol. 2019;234(8):14031–9.PubMedCrossRef
151.
Jiang Z, Slater CM, Zhou Y, Devarajan K, Ruth KJ, Li Y, et al. LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Res. 2017;19(1):1–15.CrossRef
152.
Yan M, Zhang L, Li G, Xiao S, Dai J, Cen X. Long noncoding RNA linc-ITGB1 promotes cell migration and invasion in human breast cancer. Biotechnol Appl Biochem. 2017;64(1):5–13.PubMedCrossRef
153.
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5(6): e1287.PubMedPubMedCentralCrossRef
154.
Ma T, Liang Y, Li Y, Song X, Zhang N, Li X, et al. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell Signal. 2020;68: 109536.PubMedCrossRef
155.
Huang X, Xie X, Liu P, Yang L, Chen B, Song C, et al. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018;37(49):6316–26.PubMedCrossRef
156.
Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, et al. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018;37(47):6166–79.PubMedCrossRef
157.
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Investig. 2017;127(12):4498–515.PubMedPubMedCentralCrossRef
158.
Beltrán-Anaya FO, Romero-Córdoba S, Rebollar-Vega R, Arrieta O, Bautista-Piña V, Dominguez-Reyes C, et al. Expression of long non-coding RNA ENSG 00000226738 (Lnc KLHDC 7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. Mol Oncol. 2019;13(4):909–27.PubMedPubMedCentralCrossRef
159.
Vennin C, Spruyt N, Robin Y-M, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017;385:198–206.PubMedCrossRef
160.
Richards EJ, Zhang G, Li Z-P, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015;290(11):6857–67.PubMedPubMedCentralCrossRef
161.
Jia X, Shi L, Wang X, Luo L, Ling L, Yin J, et al. KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation. Cell Death Dis. 2019;10(5):1–16.CrossRef
162.
Shi S-J, Wang L-J, Yu B, Li Y-H, Jin Y, Bai X-Z. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652.PubMedPubMedCentralCrossRef
163.
Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du Y-E, et al. LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of hedgehog signaling pathway. Stem Cells. 2016;34(1):55–66.PubMedCrossRef
164.
Yi T, Zhou X, Sang K, Huang X, Zhou J, Ge L. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway. Artif Cells Nanomed Biotechnol. 2019;47(1):3765–73.PubMedCrossRef
165.
Yang Y, Yang H, Xu M, Zhang H, Sun M, Mu P, et al. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Hum Cell. 2018;31(3):232–41.PubMedCrossRef
166.
Kwok ZH, Roche V, Chew XH, Fadieieva A, Tay Y. A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer. 2018;143(3):668–78.PubMedCrossRef
167.
Arun G, Diermeier S, Akerman M, Chang K-C, Wilkinson JE, Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34–51.PubMedPubMedCentralCrossRef
168.
Cheng Y, Pan Y, Pan Y, Wang O. MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer. Cancer Manag Res. 2019;11:803.PubMedPubMedCentralCrossRef
169.
Zhu M, Wang F, Mi H, Li L, Wang J, Han M, et al. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells. Cell Cycle. 2020;19(23):3277–88.PubMedPubMedCentralCrossRef
170.
Wang S, Ke H, Zhang H, Ma Y, Ao L, Zou L, et al. LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9(8):1–11.CrossRef
171.
Zhu D, Zhang X, Lin Y, Liang S, Song Z, Dong C. MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p. Am J Transl Res. 2019;11(1):245.PubMedPubMedCentral
172.
173.
Zhang M, Wu W, Wang Z, Wang X. lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. Eur Rev Med Pharmacol Sci. 2017;21(5):1020–6.PubMed
174.
Song X, Liu Z, Yu Z. LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis. Acta Biochim Biophys Sin. 2019;51(4):386–92.PubMedCrossRef
175.
Wu W, Chen F, Cui X, Yang L, Chen J, Zhao J, et al. LncRNA NKILA suppresses TGF-β-induced epithelial–mesenchymal transition by blocking NF-κB signaling in breast cancer. Int J Cancer. 2018;143(9):2213–24.PubMedCrossRef
176.
Jiang Y, Lin L, Zhong S, Cai Y, Zhang F, Wang X, et al. Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3β in breast cancer. J Cell Physiol. 2019;234(7):10698–708.PubMedCrossRef
177.
Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018;103:939–46.PubMedCrossRef
178.
Tan B-S, Yang M-C, Singh S, Chou Y-C, Chen H-Y, Wang M-Y, et al. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 2019;38(28):5612–26.PubMedCrossRef
179.
Yang Y-X, Wei L, Zhang Y-J, Hayano T, Pineiro Pereda MDP, Nakaoka H, et al. Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis. Clin Exp Metastasis. 2018;35(3):109–21.PubMedCrossRef
180.
Jadaliha M, Gholamalamdari O, Tang W, Zhang Y, Petracovici A, Hao Q, et al. A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability. PLoS Genet. 2018;14(11): e1007802.PubMedPubMedCentralCrossRef
181.
Liang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018;9(5):1–16.CrossRef
182.
Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y, et al. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res. 2019;38(1):1–14.CrossRef
183.
Tang J, Li Y, Sang Y, Yu B, Lv D, Zhang W, et al. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene. 2018;37(34):4723–34.PubMedCrossRef
184.
Liu B, Yao P, Xiao F, Guo J, Wu L, Yang Y. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54. J Transl Med. 2021;19(1):1–17.CrossRef
185.
186.
Liu J, Song Z, Feng C, Lu Y, Zhou Y, Lin Y, et al. The long non-coding RNA SUMO1P3 facilitates breast cancer progression by negatively regulating miR-320a. Am J Transl Res. 2017;9(12):5594.PubMedPubMedCentral
187.
Zhou B, Guo H, Tang J. Long non-coding RNA TFAP2A-AS1 inhibits cell proliferation and invasion in breast cancer via miR-933/SMAD2. Med Sci Monit Int Med J Exp Clin Res. 2019;25:1242.
188.
Liu Y, Du Y, Hu X, Zhao L, Xia W. Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer. 2018;18(1):1–11.
189.
Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother. 2017;95:1636–43.PubMedCrossRef
190.
Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer. 2017;24(4):535–43.PubMedCrossRef
191.
Li H, Zhu L, Xu L, Qin K, Liu C, Yu Y, et al. Long noncoding RNA linc00617 exhibits oncogenic activity in breast cancer. Mol Carcinog. 2017;56(1):3–17.PubMedCrossRef
192.
Li X, Wu Y, Liu A, Tang X. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop. Tumor Biol. 2016;37(11):14733–43.CrossRef
193.
Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun. 2018;498(4):1002–8.PubMedCrossRef
194.
Tariq A, Hao Q, Sun Q, Singh DK, Jadaliha M, Zhang Y, et al. LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells. RNA. 2020;26(2):175–85.PubMedPubMedCentralCrossRef
195.
Wang J, Xi C, Yang X, Lu X, Yu K, Zhang Y, et al. LncRNA WT1-AS inhibits triple-negative breast cancer cell migration and invasion by downregulating transforming growth factor β1. Cancer Biother Radiopharm. 2019;34(10):671–5.PubMed
196.
Tian Y, Xia S, Ma M, Zuo Y. LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther. 2019;12:10569.PubMedPubMedCentralCrossRef
197.
Li P, Zhou B, Lv Y, Qian Q. LncRNA HEIH regulates cell proliferation and apoptosis through miR-4458/SOCS1 axis in triple-negative breast cancer. Hum Cell. 2019;32(4):522–8.PubMedCrossRef
198.
199.
200.
Wei M, Liu L, Wang Z. Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer. Oncol Lett. 2019;18(6):6775–80.PubMedPubMedCentral
201.
Wang G, Mou Z, Xu Y, Liu G, Wang D, Zhang H. LINC01096 knockdown inhibits progression of triple-negative breast cancer by increasing miR-3130-3p. Eur Rev Med Pharmacol Sci. 2019;23(17):7445–56.PubMed
202.
Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43(7):621–9.PubMedPubMedCentralCrossRef
203.
Zou Q, Zhou E, Xu F, Zhang D, Yi W, Yao J. A TP73-AS1/miR-200a/ZEB1 regulating loop promotes breast cancer cell invasion and migration. J Cell Biochem. 2018;119(2):2189–99.PubMedCrossRef
204.
Huan J, Xing L, Lin Q, Xui H, Qin X. Long noncoding RNA CRNDE activates Wnt/β-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res. 2017;9(4):1977.PubMedPubMedCentral
205.
Wu J, Chen H, Ye M, Wang B, Zhang Y, Sheng J, et al. Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression. Biomed Pharmacother. 2019;115: 108869.PubMedCrossRef
206.
Shi Y, Lu H, Wang H. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 2019;23(4):1563–73.PubMed
207.
Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, et al. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Mol Cell Biol. 2019;39(23):e00261-e319.PubMedPubMedCentralCrossRef
208.
Sun W, Li AQ, Zhou P, Jiang YZ, Jin X, Liu YR, et al. DSCAM-AS 1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy. Cancer Med. 2018;7(12):6137–46.PubMedPubMedCentralCrossRef
209.
Feng J, Wen T, Li Z, Feng L, Zhou L, Yang Z, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging (Albany NY). 2020;12(20):20658.PubMedCrossRef
210.
Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11(1):1–15.CrossRef
211.
Du C, Wang Y, Zhang Y, Zhang J, Zhang L, Li J. LncRNA DLX6-AS1 contributes to epithelial–mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p/paxillin axis. Cell Transplant. 2020;29:0963689720929983.PubMedPubMedCentralCrossRef
212.
Zhang H, Zhang X-Y, Kang X-N, Jin L-J, Wang Z-Y. LncRNA-SNHG7 enhances chemotherapy resistance and cell viability of breast cancer cells by regulating miR-186. Cancer Manag Res. 2020;12:10163.PubMedPubMedCentralCrossRef
213.
Tang L, Chen Y, Chen H, Jiang P, Yan L, Mo D, et al. DCST1-AS1 promotes TGF-β-induced epithelial-mesenchymal transition and enhances chemoresistance in triple-negative breast cancer cells via ANXA1. Front Oncol. 2020;10:280.PubMedPubMedCentralCrossRef
214.
Wang Z, Katsaros D, Biglia N, Shen Y, Loo L, Yu X, et al. ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer. Breast Cancer Res Treat. 2019;175(2):353–68.PubMedPubMedCentralCrossRef
215.
Dong H, Wang W, Mo S, Chen R, Zou K, Han J, et al. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res. 2018;37(1):1–15.CrossRef
216.
Dong H, Wang W, Mo S, Liu Q, Chen X, Chen R, et al. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation. J Cell Mol Med. 2018;22(10):4935–47.PubMedPubMedCentralCrossRef
217.
Pan Y, Pan Y, Cheng Y, Yang F, Yao Z, Wang O. Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers. Cell Biosci. 2018;8(1):1–13.CrossRef
218.
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.PubMedCrossRef
219.
Wang R, Zhang T, Yang Z, Jiang C, Seng J. Long non-coding RNA FTH 1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB 1. J Cell Mol Med. 2018;22(9):4068–75.PubMedPubMedCentralCrossRef
220.
Yang F, Liu Y-H, Dong S-Y, Ma R-M, Bhandari A, Zhang X-H, et al. A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer. Biochem Biophys Res Commun. 2016;470(3):479–83.PubMedCrossRef
221.
222.
García-Venzor A, Mandujano-Tinoco EA, Ruiz-Silvestre A, Sánchez JM, Lizarraga F, Zampedri C, et al. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells. Carcinogenesis. 2020;41(11):1485–97.PubMedCrossRef
223.
Sun W, Xu X, Jiang Y, Jin X, Zhou P, Liu Y, et al. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. Int J Cancer. 2019;145(3):842–56.PubMed
224.
Zeng Y, Wang G, Zhou C-F, Zhang H-B, Sun H, Zhang W, et al. LncRNA profile study reveals a three-LncRNA signature associated with the pathological complete response following neoadjuvant chemotherapy in breast cancer. Front Pharmacol. 2019;10:574.PubMedPubMedCentralCrossRef
225.
Yao N, Fu Y, Chen L, Liu Z, He J, Zhu Y, et al. Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene. 2019;38(47):7216–33.PubMedCrossRef
226.
Yu F, Wang L, Zhang B. Long non-coding RNA DRHC inhibits the proliferation of cancer cells in triple negative breast cancer by downregulating long non-coding RNA HOTAIR. Oncol Lett. 2019;18(4):3817–22.PubMedPubMedCentral
227.
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004;101(10):3329–35.PubMedPubMedCentralCrossRef
228.
Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23(2):143–58.PubMedPubMedCentralCrossRef
229.
Jiang Y, Qian T, Li S, Xie Y, Tao M. Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Ann Transl Med. 2022;10(6):366.PubMedPubMedCentralCrossRef
230.
Golshan M, Khaleghi S, Shafiee SM, Valaee S, Ghanei Z, Jamshidizad A, et al. Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial–mesenchymal transition in MDA-MB-231 cells. J Cell Biochem. 2021;122(3–4):385–93.PubMedCrossRef
231.
Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):1–12.CrossRef
232.
233.
Guo Z, Zhao M, Howard EW, Zhao Q, Parris AB, Ma Z, et al. Phenformin inhibits growth and epithelial–mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway. Oncotarget. 2017;8(36):60342.PubMedPubMedCentralCrossRef
234.
Chen J, Zheng G, Guo H, Shi Z-N, Jiang J, Wang X-Y, et al. The effect of metformin treatment on endoplasmic reticulum (ER) stress induced by status epilepticus (SE) via the PERK-eIF2α-CHOP pathway. Bosn J Basic Med Sci. 2018;18(1):49.PubMedPubMedCentral
235.
Wang J, Sun J, Yang F. The role of long non-coding RNA H19 in breast cancer. Oncol Lett. 2020;19(1):7–16.PubMed
236.
Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A, Gutti RK. Long non-coding RNA: classification, biogenesis and functions in blood cells. Mol Immunol. 2019;112:82–92.PubMedCrossRef
237.
Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012;14(7):659–65.PubMedPubMedCentralCrossRef
238.
Chen J, Qin C, Zhou Y, Chen Y, Mao M, Yang J. Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer. FEBS Open Bio. 2022;12(1):146–53.PubMedCrossRef
239.
Lin H-Y, Ho H-W, Chang Y-H, Wei C-J, Chu P-Y. The evolving role of ferroptosis in breast cancer: translational implications present and future. Cancers. 2021;13(18):4576.PubMedPubMedCentralCrossRef
240.
Wang D, Tang L, Zhang Y, Ge G, Jiang X, Mo Y, et al. Regulatory pathways and drugs associated with ferroptosis in tumors. Cell Death Dis. 2022;13(6):1–15.CrossRef
241.
Guo J, Li Y, Duan H, Yuan L. Metformin suppresses the proliferation and promotes the apoptosis of colon cancer cells through inhibiting the expression of long noncoding RNA-UCA1. Onco Targets Ther. 2020;13:4169.PubMedPubMedCentralCrossRef
242.
Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34(23):3076–84.PubMedCrossRef
243.
Aminimoghaddam S, Fooladi B, Noori M, Klashami ZN, Hamidi AK, Amoli MM. The effect of metformin on expression of long non-coding RNA H19 in endometrial cancer. Med J Islam Repub Iran. 2021;35:155.PubMedPubMedCentral
244.
Xia C, Liang S, He Z, Zhu X, Chen R, Chen J. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. Eur J Pharmacol. 2018;830:59–67.PubMedCrossRef
245.
Qiu C, Li C, Zheng Q, Fang S, Xu J, Wang H, et al. Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163. Bioengineered. 2022;13(5):11987–2002.PubMedPubMedCentralCrossRef
246.
Wu P, Tang Y, Fang X, Xie C, Zeng J, Wang W, et al. Metformin suppresses hypopharyngeal cancer growth by epigenetically silencing long non-coding RNA SNHG7 in FaDu cells. Front Pharmacol. 2019;10:143.PubMedPubMedCentralCrossRef
247.
248.
Tseng H-H, Chen Y-Z, Chou N-H, Chen Y-C, Wu C-C, Liu L-F, et al. Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis. Mol Ther Oncolytics. 2021;22:180–94.PubMedPubMedCentralCrossRef
249.
Sabry D, Abdelaleem OO, El Amin Ali AM, Mohammed RA, Abdel-Hameed ND, Hassouna A, et al. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. Mol Biol Rep. 2019;46(2):2039–47.PubMedCrossRef
250.
Jiang Z, Liu H. Metformin inhibits tumorigenesis in HBV-induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX. J Cell Biochem. 2018;119(6):4482–95.PubMedCrossRef
Metadata
Title
Metformin and long non-coding RNAs in breast cancer
Authors
Morteza Gholami
Zeynab Nickhah Klashami
Pirooz Ebrahimi
Amir Ali Mahboobipour
Amir Salehi Farid
Aida Vahidi
Marziyeh Zoughi
Mojgan Asadi
Mahsa M. Amoli
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-03909-x

Other articles of this Issue 1/2023

Journal of Translational Medicine 1/2023 Go to the issue

Research

Intestinal epithelium-specific Fut2 deficiency promotes colorectal cancer through down-regulating fucosylation of MCAM

Research

Gene’s expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study

Research

Protectin conjugates in tissue regeneration 1 alleviates sepsis-induced acute lung injury by inhibiting ferroptosis

Research

Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1

Research

The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma

Research

Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits